SHAHBAZ KHAN: Open Payments
NPI 1619048295 · CONCORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,343 in 125 payments from 15 companies in 2025. Trend: 2023 $2,986 · 2024 $3,314 · 2025 $4,343
Food & beverage: $4,243Education: $100
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $647 |
| E.R. Squibb & Sons, L.L.C. | 14 | $613 |
| Axsome Therapeutics, Inc. | 13 | $483 |
| ABBVIE INC. | 19 | $434 |
| Teva Pharmaceuticals USA, Inc. | 7 | $400 |
| Otsuka America Pharmaceutical, Inc. | 11 | $379 |
| Vanda Pharmaceuticals Inc. | 11 | $375 |
| Neurocrine BioSciences, Inc. | 11 | $371 |
| Janssen Pharmaceuticals, Inc | 4 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $170 |
Products named: COBENFY, Auvelity, REXULTI, VRAYLAR, ARISTADA, FANAPT, INGREZZA, LYBALVI.
Industry payments across CA — which companies pay providers there.
